Table 2 Posted results of first-line combination regimen trials for pembrolizumab, nivolumab, and atezolizumab in advanced NSCLC
From: Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Identifier | Trials | Agent | Phase | Population | Arms | Biomarkers | ORR | mPFS | 1 year PFS rate | mOS | 1 year OS rate | mDOR | Adverse Effects Rate (≥ grade 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT02039674 | Keynote 021 | Pembrolizumab | II | Untreated metastatic Non-squamous NSCLC Without EGFR/ALK alteration | Pembrolizumab + platinum | Regardless PD-L1 | 55.00% | 24 m | NA | NR | NA | NA | 39.00% |
Platinum | 29.00% | 9.3Â m | 21.1Â m | 26.00% | |||||||||
NCT02578680 | Keynote 189 | Pembrolizumab | III | Untreated metastatic Non-squamous NSCLC Without EGFR/ALK alteration | Pembrolizumab + platinum | Regardless PD-L1 | 47.60% | 8.8 m | 34.10% | NR | 69.20% | 11.2 m | 67.20% |
Platinum | 18.90% | 4.9Â m | 17.30% | 11.3Â m | 49.90% | 7.8Â m | 65.80% | ||||||
NCT02775435 | Keynote 407 | Pembrolizumab | III | Untreated metastatic, squamous NSCLC | Pembrolizumab + platinum | Regardless PD-L1 | 57.90% | 6.4 m | NA | 15.9 m | 65.20% | 7.7 m | 69.80% |
platinum | 38.40% | 4.8Â m | NA | 11.3Â m | 48.30% | 4.8Â m | 68.20% | ||||||
NCT02477826 | Checkmate 227 | Nivolumab | III | Untreated metastatic Non-squamous NSCLC Without EGFR/ALK alteration | Nivolumab + platinum | TMB ≥ 10mut/Mb | 60.50% | NA | 27.00% | NA | NA | NA | NA |
Nivolumab + ipilimumab | 45.30% | 7.2 m | 45.00% | 31.20% | |||||||||
Platinum | 27.00% | 5.4Â m | 13.20% | 36.10% | |||||||||
NCT02657434 | Impower 131 | Atezolizumab | III | Treatment-naïve Stage IV squamous NSCLC | Atezolizumoab + carboplatin | ITT population | 49.00% | 6.3 m | 24.00% | 14.0 m | 55.60% | NA | 69.00% |
Carboplatin | 41.00% | 5.6Â m | 12.00% | 13.9Â m | 56.80% | 58.00% | |||||||
2NCT02657434 | Impower132 | Atezolizumab12 | III | Non-squamous NSCLC Without EGFR/ALK alterationUntreated metastatic | Atezolizumoab + carboplatin | ITT population | 47.00% | 7.6 m | 33.70% | 18.1 m | 59.60% | 10.1 m | 69.00% |
Carboplatin | 32.00% | 5.2Â m | 13.6Â m | 59.00% | |||||||||
NCT02659059 | Checkmate 568 | Nivolumab | II | Untreated metastatic Non-squamous NSCLC Without EGFR/ALK alteration | Nivolumab plus low-dose ipilimumab | PD-L1 < 1% | 41.00% | 6.8 m | 52%a | NA | NA | NA | 29.00% |
PD-L1 ≥ 1% | 15.00% | 2.8 m | 32%a |  |  |  |  | ||||||
TMB ≥ 10 mut/Mb | 44.00% | 7.1 m | 55%a |  |  |  |  | ||||||
TMb < 10 mut/Mb | 12.00% | 2.6 m | 31%a |  |  |  |  |